Clinical Trials | September 16, 2025
Novo Nordisk’s amylin therapy cagrilintide shows significant weight loss in phase 3 trial
Cagrilintide represents a novel approach to obesity management
Cagrilintide represents a novel approach to obesity management
This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Bain Capital and Cinven will each retain a minority stake, reflecting their ongoing confidence in STADA’s future growth
Enlicitide achieved all primary and key secondary endpoints, demonstrating statistically significant and clinically meaningful reductions in low-density lipoprotein cholesterol
The trial is the largest to date evaluating Leqvio and the first to focus on patient-centered outcomes
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
Accro will retain global rights to develop, manufacture, and commercialize AC-201 (excluding Chinese Mainland, Hong Kong SAR, and Macau SAR)
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
